Inflammatory bowel disease (IBD) is a general term for chronic or remitting/relapsing
inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) …

Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Introduction Ustekinumab, an interleukin-12 and interleukin-23 antagonist, is licensed for the
treatment of Crohn's disease (CD) and ulcerative colitis (UC) after the phase III trial …

Background The prevalence of inflammatory bowel diseases (IBD) is high in women of
childbearing age. Achieving clinical remission from conception to delivery using current …

Two new biological drugs (vedolizumab and ustekinumab) and one small molecule
(tofacitinib) have been recently approved for the treatment of inflammatory bowel disease …

Background Ustekinumab [UST] is effective in Crohn's disease (CD) in the UNITI studies.
Several real-world experience (RWE) studies with UST have been published to date. Our …

Introduction: The peak age of diagnosis of inflammatory bowel disease (IBD) occurs during
childbearing years, therefore management of IBD during pregnancy is a frequent …

Females are generally more affected by autoimmune diseases, a fact that underlines the
relationship with pregnancy and the safety of anti-rheumatic drugs in pregnancy and …

Ustekinumab [UST] therapy during pregnancy has not yet been extensively evaluated in
patients with Crohn's disease. Here, we present the case of a 24-year-old woman with …

Introduction: Biological agents have radically changed the prognosis of rheumatic patients.
Current evidence demonstrates that tight disease control during pregnancy is mandatory to …